NewAmsterdam Pharma Company NV’s recent filing unveils that its Affiliate NAP PoolCo B.V. acquired Company’s shares for reported $21.67 million on Apr 11 ’25. In the deal valued at $15.12 per share,1,433,193 shares were bought.
Then, Topper James N bought 1,135 shares, generating $25,521 in total proceeds. Upon buying the shares at $22.49, the Director now owns 3,013,569 shares.
Before that, Michael H. Davidson bought 12,258 shares. NewAmsterdam Pharma Company NV shares valued at $286,960 were divested by the Affiliate at a price of $23.41 per share.
H.C. Wainwright initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published on December 30, 2024; the price target was $48. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Scotiabank began covering NAMS with “Sector outperform” recommendation on March 14, 2024. Guggenheim started covering the stock on January 18, 2024. It rated NAMS as “a Buy”.
Price Performance Review of NAMS
On Monday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock jump 8.60% to $16.42. Over the last five days, the stock has gained 3.53%. NewAmsterdam Pharma Company NV shares have fallen nearly -36.11% since the year began. Nevertheless, the stocks have fallen -17.61% over the past one year. While a 52-week high of $27.29 was reached on 01/02/25, a 52-week low of $14.06 was recorded on 04/07/25. SMA at 50 days reached $20.42, while 200 days put it at $20.01.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 15.38, which if violated will result in even more drops to 14.33. On the upside, there is a resistance level at 17.01. A further resistance level may holdings at 17.59. The Relative Strength Index (RSI) on the 14-day chart is 34.86, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.44, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.57%. Stochastics %K at 14.57% indicates the stock is a buying.
How much short interest is there in NewAmsterdam Pharma Company NV?
A steep rise in short interest was recorded in NewAmsterdam Pharma Company NV stocks on 2025-03-31, growing by 2.3 million shares to a total of 5.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 3.04 million shares. There was a rise of 43.07%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 16, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $37 price target.
